Pyxis Oncology, Inc. — Director's Dealing 2021

Oct 8, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2021-10-07

Reporting Person: FLAVIN JOHN L (N/A)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	169222	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$		Common Stock (2388)		Direct
Stock Option (Right to buy)	$8.71	2031-08-18	Common Stock (15725)		Direct

Footnotes

F1: Includes 47,593 shares of restricted stock that are subject to vesting in six, substantially-equal quarterly installments beginning October 22, 2021, subject to the reporting person's continued service through the applicable vesting date.

F2: Each 6.359 shares of Series B Convertible Preferred Stock are currently convertible into one share of Common Stock at the option of the holder, for no additional consideration, and will convert automatically upon completion of the Issuer's initial public offering (with fractional shares paid out in cash). These shares have no expiration date.

F3: These stock options vest in three, substantially-equal annual installments beginning on the first anniversary of the August 19, 2021 grant date, subject to the reporting person's continued service through the applicable vesting date.